215 related articles for article (PubMed ID: 22008906)
21. Carbon Monoxide-Releasing Molecule Enhances Coagulation and Decreases Fibrinolysis in Normal Canine Plasma.
Donaghy D; Yoo S; Johnson T; Nielsen V; Olver C
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):257-262. PubMed ID: 29577635
[TBL] [Abstract][Full Text] [Related]
22. Carbon monoxide releasing molecule-2 enhances coagulation in rat and rabbit plasma.
Nielsen VG; Huneke RB; Khan ES
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):298-9. PubMed ID: 20351645
[No Abstract] [Full Text] [Related]
23. Crotalus atrox Venom Exposed to Carbon Monoxide Has Decreased Fibrinogenolytic Activity In Vivo in Rabbits.
Nielsen VG
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):82-86. PubMed ID: 28691277
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the effects of CORM-2, CORM-3 and CORM-A1 on coagulation in human plasma.
Nielsen VG; Garza JI
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):801-5. PubMed ID: 25058038
[TBL] [Abstract][Full Text] [Related]
25. Carbon monoxide releasing molecule-2 increases fibrinogen-dependent coagulation kinetics but does not enhance prothrombin activity.
Nielsen VG; Malayaman SN; Khan ES; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2010 Jun; 21(4):349-53. PubMed ID: 20449889
[TBL] [Abstract][Full Text] [Related]
26. Iron and carbon monoxide attenuate degradation of plasmatic coagulation by Crotalus atrox venom.
Nielsen VG; Boyer LV
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):506-10. PubMed ID: 26575491
[TBL] [Abstract][Full Text] [Related]
27. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
Herbert JM; Dol F; Bernat A; Falotico R; Lalé A; Savi P
Thromb Haemost; 1998 Sep; 80(3):512-8. PubMed ID: 9759636
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context.
Vadori M; Seveso M; Besenzon F; Bosio E; Tognato E; Fante F; Boldrin M; Gavasso S; Ravarotto L; Mann BE; Simioni P; Ancona E; Motterlini R; Cozzi E
Xenotransplantation; 2009; 16(2):99-114. PubMed ID: 19392725
[TBL] [Abstract][Full Text] [Related]
29. Exogenous carbon monoxide suppresses Escherichia coli vitality and improves survival in an Escherichia coli-induced murine sepsis model.
Shen WC; Wang X; Qin WT; Qiu XF; Sun BW
Acta Pharmacol Sin; 2014 Dec; 35(12):1566-76. PubMed ID: 25399652
[TBL] [Abstract][Full Text] [Related]
30. Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammation in the liver of septic mice.
Cepinskas G; Katada K; Bihari A; Potter RF
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G184-91. PubMed ID: 17991708
[TBL] [Abstract][Full Text] [Related]
31. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
32. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Vilahur G; Casaní L; Badimon L
Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
[TBL] [Abstract][Full Text] [Related]
33. Iron and carbon monoxide prevent degradation of plasmatic coagulation by thrombin-like activity in rattlesnake venom.
Nielsen VG
Hum Exp Toxicol; 2016 Oct; 35(10):1116-22. PubMed ID: 26666988
[TBL] [Abstract][Full Text] [Related]
34. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
[TBL] [Abstract][Full Text] [Related]
35. Carbon monoxide releasing molecule enhances coagulation and decreases fibrinolysis in canine plasma exposed to Crotalus viridis venom in vitro and in vivo.
Johnson TE; Wells RJ; Bell A; Nielsen VG; Olver CS
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):328-336. PubMed ID: 31059181
[TBL] [Abstract][Full Text] [Related]
36. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
Dallob A; Luo WL; Luk JM; Ratcliffe L; Johnson-Levonas AO; Schwartz JI; Dishy V; Kraft WK; De Hoon JN; Van Hecken A; De Lepeleire I; Radziszewski W; Wagner JA; Lai E
Platelets; 2011; 22(7):495-503. PubMed ID: 21526889
[TBL] [Abstract][Full Text] [Related]
37. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
38. CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic stroke.
Yabluchanskiy A; Sawle P; Homer-Vanniasinkam S; Green CJ; Foresti R; Motterlini R
Crit Care Med; 2012 Feb; 40(2):544-52. PubMed ID: 21926571
[TBL] [Abstract][Full Text] [Related]
39. Investigation into the mechanism(s) of antithrombotic effects of carbon monoxide releasing molecule-3 (CORM-3).
Soni H; Jain M; Mehta AA
Thromb Res; 2011 Jun; 127(6):551-9. PubMed ID: 21376373
[TBL] [Abstract][Full Text] [Related]
40. Carbon monoxide releasing molecule-2 inhibition of snake venom thrombin-like activity: novel biochemical "brake"?
Nielsen VG; Bazzell CM
J Thromb Thrombolysis; 2017 Feb; 43(2):203-208. PubMed ID: 27787696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
